These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 28314589

  • 1. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.
    Gynecol Oncol; 2017 May; 145(2):366-373. PubMed ID: 28314589
    [Abstract] [Full Text] [Related]

  • 2. Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma.
    Liu T, Willmore-Payne C, Wallander ML, Layfield LJ.
    Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):341-6. PubMed ID: 21285871
    [Abstract] [Full Text] [Related]

  • 3. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.
    Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM.
    PLoS One; 2012 Jul; 7(2):e30801. PubMed ID: 22383975
    [Abstract] [Full Text] [Related]

  • 4. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P.
    Gynecol Oncol; 2015 Sep; 138(3):614-9. PubMed ID: 26144601
    [Abstract] [Full Text] [Related]

  • 5. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R.
    Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA, Loch DC, Pollock PM.
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [Abstract] [Full Text] [Related]

  • 7. FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
    Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM.
    Gynecol Oncol; 2010 Apr; 117(1):125-9. PubMed ID: 20106510
    [Abstract] [Full Text] [Related]

  • 8. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.
    Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ.
    J Clin Oncol; 2009 Jul 01; 27(19):3091-6. PubMed ID: 19470935
    [Abstract] [Full Text] [Related]

  • 9. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.
    Sengal AT, Smith D, Snell CE, Leung S, Talhouk A, Williams ED, McAlpine JN, Pollock PM.
    J Pathol Clin Res; 2022 Nov 01; 8(6):521-537. PubMed ID: 35866380
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Carr C, Son J, Yao M, Priyadarshini A, Marquard J, Vargas R, Michener C, AlHilli MM.
    Gynecol Oncol; 2020 Dec 01; 159(3):712-720. PubMed ID: 33046272
    [Abstract] [Full Text] [Related]

  • 11. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis.
    Casanova J, Duarte GS, da Costa AG, Catarino A, Nave M, Antunes T, Serra SS, Dias SS, Abu-Rustum N, Lima J.
    Gynecol Oncol; 2024 Mar 01; 182():99-107. PubMed ID: 38262245
    [Abstract] [Full Text] [Related]

  • 12. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
    Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM.
    Mol Oncol; 2019 Apr 01; 13(4):738-756. PubMed ID: 30537101
    [Abstract] [Full Text] [Related]

  • 13. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
    Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK.
    Gynecol Oncol; 2017 Aug 01; 146(2):247-253. PubMed ID: 28532857
    [Abstract] [Full Text] [Related]

  • 14. FGFR2 alterations in endometrial carcinoma.
    Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, Dolcet X, Prat J, Matias-Guiu X.
    Mod Pathol; 2011 Nov 01; 24(11):1500-10. PubMed ID: 21725289
    [Abstract] [Full Text] [Related]

  • 15. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.
    Gynecol Oncol; 2018 Jan 01; 148(1):174-180. PubMed ID: 29132872
    [Abstract] [Full Text] [Related]

  • 16. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A, Kuick CH, Wong WL, Tham JM, Mansor S, Loh E, Jain S, Vikas NN, Tan SH, Chan SH, Li ST, Chew SH, Hong W, Ngeow J.
    Gynecol Oncol; 2016 Apr 01; 141(1):113-20. PubMed ID: 26748215
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.
    Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ.
    Oncogene; 2007 Nov 01; 26(50):7158-62. PubMed ID: 17525745
    [Abstract] [Full Text] [Related]

  • 19. FGFR2 as a molecular target in endometrial cancer.
    Byron SA, Pollock PM.
    Future Oncol; 2009 Feb 01; 5(1):27-32. PubMed ID: 19243295
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
    Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.
    Cancer Res; 2008 Sep 01; 68(17):6902-7. PubMed ID: 18757403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.